Last reviewed · How we verify
Rabbit Anti-Human Thymocyte Globulin
Rabbit Anti-Human Thymocyte Globulin works by depleting T lymphocytes, thereby reducing the immune response.
Rabbit Anti-Human Thymocyte Globulin works by depleting T lymphocytes, thereby reducing the immune response. Used for Prevention of organ rejection in kidney transplant patients, Treatment of aplastic anemia.
At a glance
| Generic name | Rabbit Anti-Human Thymocyte Globulin |
|---|---|
| Also known as | ATG-S FRESENIUS |
| Sponsor | Dr. Claudia Bösmüller |
| Drug class | Monoclonal antibody |
| Target | T cells |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to the surface of T cells, marking them for destruction, and ultimately reducing the number of T cells in the body. This can help prevent the rejection of transplanted organs and treat certain autoimmune diseases.
Approved indications
- Prevention of organ rejection in kidney transplant patients
- Treatment of aplastic anemia
Common side effects
- Thrombocytopenia
- Leukopenia
- Anemia
- Infection
- Bleeding
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility (NA)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
- Immune Tolerance Induction After Liver Transplantation (PHASE1, PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabbit Anti-Human Thymocyte Globulin CI brief — competitive landscape report
- Rabbit Anti-Human Thymocyte Globulin updates RSS · CI watch RSS
- Dr. Claudia Bösmüller portfolio CI